Asia-Pacific and Middle East NGS Market to 2027: Increasing Adoption of NGS in Various Research and Diagnostics Fields Drives Growth - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Asia-Pacific and Middle East NGS Market: Focus on Offering, Platform, Throughput, Technology Type, Application, End User, and Country Analysis - Analysis and Forecast, 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The Asia-Pacific and Middle East NGS market was valued at $1,055.6 million in 2022 and is anticipated to reach $2,370.7 million by 2027, witnessing a CAGR of 17.56% during the forecast period 2022-2027.

The market is driven by factors such as the increasing adoption of NGS in various research and diagnostics fields, growing prevalence of non-communicable disorders, and advancement in the performance of NGS platforms.

Market Lifecycle Stage

The Asia-Pacific and Middle East NGS market is highly consolidated. This market still holds significant potential for growth as technological developments in NGS platforms and initiatives to integrate genomics in healthcare are ongoing.

The opportunity for growth of the Asia-Pacific and Middle East NGS market lies in development of economical and portable technologies.

Recent Developments in the Asia-Pacific and Middle East NGS Market

• In October 2022, the company introduced Revio and Onso - new sequencing systems; Revio is a long-read sequencing system that allows the sequencing of up to 1,300 human whole genomes per year, while Onso is a benchtop short-read DNA sequencing platform. The system enables scaling of the use of PacBio's HiFi sequencing technology for large studies in human genetics, cancer research, and agricultural genomics, among others.
• In September 2022, Illumina, Inc. introduced Illumina Complete Long-Reads (INFINITY) for human whole-genome sequencing (WGS). This resulted in a high-performance, streamlined, integrated method. Furthermore, the platform showed compatibility with all NovaSeq systems for the synthesis of thousands of long-read genomes every year.
• In September 2022, Illumina, Inc. introduced the first FDA-registered and CE-marked in vitro diagnostic (IVD) high-throughput sequencer, the NovaSeq 6000 Dx. The NovaSeq 6000 Dx is a versatile platform that provides the greatest levels of compliance while also delivering useful insights for patient care.
• In August 2022, Illumina, Inc. teamed with Minderoo Foundation and contributed $27.8 million to improve genetic knowledge of marine systems. This innovative collaboration used Illumina's NextSeq 2000 sequencing system to assess and understand marine life in seas.

Demand - Drivers and Limitations

The following are the drivers for the Asia-Pacific and Middle East NGS market:

• Increasing Adoption of NGS in Various Research and Diagnostics Fields
• Growing Prevalence of Non-Communicable Diseases
• Advancement in the Performance of NGS Platforms

The market is expected to face some limitations as well due to the following challenges:

• Dearth of Skilled Professionals in Middle East Countries
• High Cost of Installation and Maintenance of the Equipment
• Reimbursement and Regulatory Policies of NGS

Key Attributes:

Report Attribute	Details
No. of Pages	217
Forecast Period	2022 - 2027
Estimated Market Value (USD) in 2022	$1055.6 Million
Forecasted Market Value (USD) by 2027	$2370.7 Million
Compound Annual Growth Rate	17.6%
Regions Covered	Asia Pacific, Middle East

Key Companies Profiled

• BGI Group
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Pacific Biosciences of California, Inc.
• Oxford Nanopore Technologies plc.

Market Segmentation

Segmentation 1: by Offerings

• Consumables
• Equipment
• Services

The Asia-Pacific and Middle East NGS market (by offerings) is expected to be dominated by the consumables segment.

Segmentation 2: by Platform

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Pacific BioSciences of California, Inc.
• Oxford Nanopore Technologies plc.
• Other Companies

The Asia-Pacific and Middle East NGS market (by platform) is expected to be dominated by Illumina, Inc.

Segmentation 3: by Throughput

• High-Throughput
• Medium-Throughput
• Low-Throughput

The Asia-Pacific and Middle East NGS market (by throughput) is expected to be dominated by the high-throughput segment.

Segmentation 4: by Technology Type

• Sequencing by Synthesis
• Ion Torrent Semiconductor Sequencing
• Single Molecule Real-Time Sequencing
• Nanopore Sequencing Technology
• Other Technologies

The Asia-Pacific NGS market (by technology type) is expected to be dominated by the sequencing by synthesis segment.

Segmentation 5: by Application

• Clinical Diagnostics
• Translational Research
• Other Applications

The Asia-Pacific NGS market (by application) is expected to be dominated by the translational research segment.

Segmentation 6: by End User

• Academic and Research Institutes
• Clinical Laboratories
• Pharmaceutical and Biotechnology Companies
• Other End Users

The Asia-Pacific NGS market (by end-user) is expected to be dominated by the academic and research institutes segment.

Segmentation 7: by Country

• Asia-Pacific (Japan, India, South Korea, Australia, Singapore, New Zealand, Rest-of-Asia-Pacific)
• Middle East (U.A.E., K.S.A., Egypt, Israel, Rest-of-Middle East)

The Asia-Pacific NGS market (by country) is expected to be dominated by Japan and the Middle East NGS market (by country) is expected to be dominated by the U.A.E.

For more information about this report visit https://www.researchandmarkets.com/r/msxwqe

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.